Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Chemomab Therapeutics Ltd ADR (CMMB)

Chemomab Therapeutics Ltd ADR (CMMB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,265
  • Shares Outstanding, K 6,155
  • Annual Sales, $ 0 K
  • Annual Income, $ -13,950 K
  • EBIT $ -11 M
  • EBITDA $ -11 M
  • 60-Month Beta 0.50
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.14

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.20
  • Number of Estimates 1
  • High Estimate -0.20
  • Low Estimate -0.20
  • Prior Year -0.64
  • Growth Rate Est. (year over year) +68.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.36 +5.08%
on 11/24/25
2.85 -12.96%
on 11/18/25
-0.19 (-7.12%)
since 11/05/25
3-Month
2.36 +5.08%
on 11/24/25
3.58 -30.73%
on 10/07/25
-0.61 (-19.74%)
since 09/05/25
52-Week
2.36 +5.08%
on 11/24/25
9.84 -74.80%
on 01/07/25
-4.12 (-62.42%)
since 12/05/24

Most Recent Stories

More News
Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology

— New Peer-Reviewed Publication Highlights Phase 2 SPRING Trial Data Supporting the Disease Modifying Potential of Nebokitug in PSC and Supports Advancement to a P hase 3 Registration...

CMMB : 2.48 (+0.40%)
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit

TEL AVIV, Israel, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

CMMB : 2.48 (+0.40%)
Chemomab Announces Multiple Presentations at AASLD The Liver Meeting® 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis

— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks— —New Clinical Data...

CMMB : 2.48 (+0.40%)
Chemomab Therapeutics to Present at H.C. Wainwright 27th Annual Global Investment Conference

TEL AVIV, Israel, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory...

CMMB : 2.48 (+0.40%)
Chemomab Therapeutics Announces Second Quarter 2025 Financial Results and Provides Corporate Update

— Phase 3 Preparations Ongoing as Company Continues to Advance Multiple Partnering Options for Executing the Nebokitug Phase 3 Program— —Phase 2 SPRING Trial Data Highlighting Nebokitug’s...

CMMB : 2.48 (+0.40%)
Chemomab Announces Oral Presentation of Positive Nebokitug Phase 2 Clinical Data in Primary Sclerosing Cholangitis at BSG Live’25

CMMB : 2.48 (+0.40%)
Chemomab Reports Positive Feedback From Two Recent FDA Meetings Supporting Phase 3 Advancement of Nebokitug in Primary Sclerosing Cholangitis

CMMB : 2.48 (+0.40%)
KURA Stock Rises More Than 15% This Past Week: Here's Why

Shares of Kura Oncology KURA have rallied 15.5% in the past week against the industry’s decline of 0.1%. Earlier this week, the FDA accepted the company’s new drug application (NDA) seeking full approval...

CMMB : 2.48 (+0.40%)
LXRX : 1.4000 (-1.41%)
AMRN : 16.54 (+0.49%)
KURA : 11.95 (-0.25%)
Chemomab Announces New Patent Awards for Its First-in-Class Agent Nebokitug that is Positioned to Potentially Become the First Approved Drug for Primary Sclerosing Cholangitis

CMMB : 2.48 (+0.40%)
CADL Up as FDA Grants RMAT Status to CAN-2409 in Prostate Cancer

Candel Therapeutics CADL announced that the FDA has granted the Regenerative Medicine Advanced Therapy (RMAT) designation to its investigational adenovirus immunotherapy candidate, CAN-2409 (aglatimagene...

CMMB : 2.48 (+0.40%)
LXRX : 1.4000 (-1.41%)
AMRN : 16.54 (+0.49%)
CADL : 5.33 (+1.33%)

Business Summary

Chemomab Ltd. is a clinical-stage biotech company. It focuses on the discovery and development of innovative therapeutics for fibrosis-related diseases with high unmet need. The company's product pipeline includes CM-101. Chemomab Ltd., formerly known as Anchiano Therapeutics Ltd., is based in TEL-AVIV,...

See More

Key Turning Points

3rd Resistance Point 2.75
2nd Resistance Point 2.68
1st Resistance Point 2.58
Last Price 2.48
1st Support Level 2.41
2nd Support Level 2.35
3rd Support Level 2.25

See More

52-Week High 9.84
Fibonacci 61.8% 6.98
Fibonacci 50% 6.10
Fibonacci 38.2% 5.22
Last Price 2.48
52-Week Low 2.36

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar